“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

ARCA Biopharma


ARCA Biopharma products

Gencaro (bucindolol hydrochloride)
Indication: Genetically-targeted therapy for prevention of atrial fibrillation (AF) in heart failure patients with a specific ADRB1 genotype
Status: Completed Phase 2b (GENETIC-AF); planning for a genetically targeted Phase 3 (PRECISION-AF) under SPA agreement

rNAPc2 (recombinant nematode anticoagulant protein c2)
Indication: Investigated as a tissue-factor inhibitor with anticoagulant and anti-inflammatory potential—evaluated for hospitalized COVID-19 patients and metastatic colorectal carcinoma
Status: Phase 2 trial in COVID-19 completed; other programs suspended

NU172
Indication: Short-acting thrombin inhibitor for anticoagulation during cardiac surgery (e.g., off-pump CABG)
Status: Evaluated in Phase 2 surgical setting

Alfimeprase
Indication: Fibrinolytic for acute arterial occlusion and ischemic stroke
Status: Development discontinued after early trials

AB201 (rNAPc2 for COVID-19; IND name)
Indication: Tissue factor inhibitor for treating COVID-19-associated coagulopathy
Status: Received FDA IND approval; Phase 2 trial completed



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)